Lewis L. Lanier

This study modifies FcεR1γ with a 4-1BB co-stimulatory motif to enhance NK cell function against HLA-E+ cells, improving cytotoxicity in suppression-prone conditions.

This paper develops a genome engineering workflow for primary human NK cells using CRISPR/Cas9 and AAV6 to integrate and disrupt genes, enhancing anti-tumor function through targeted CAR expression.

This study shows that SYK negatively regulates NK cell signaling and that its deletion enhances CD19-CAR NK cell efficacy in cancer immunotherapy.

This study shows that NK cell receptor signaling and activation vary with cell cycle stages, with some proteins showing non-monotonic abundance changes.

The paper uses CITE-seq to analyze NK cell alterations in CAD patients, finding SPON2/IFNG ratio and adaptive NK cell signatures correlate with disease severity and inflammation.

This study shows PVRL2 suppresses anti-tumor immunity independently of PVRIG and TIGIT, with deletion reducing tumor growth more than PD-L1 loss.